RA Capital
About RA Capital
RA Capital Management ("RA Capital") is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization. RA Capital's scientifically trained research team is intensely data driven in its continual effort to identify early breakthroughs and originate conviction in new ideas. The team's understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.
Recent News
Recent Deals
RA Capital Planetary Health Closes $120M Fund
Azalea Therapeutics Secures $82M in Series A Funding Led by Third Rock Ventures
VitriVax Raises $17.25M Series B to Advance Thermostable Vaccine Technology
Parabilis Medicines Secures $305M Series F Funding Led by RA Capital, Fidelity Management, and Janus Henderson
Triana Biomedicines Secures $120M Series B Funding Led by Ascenta Capital and Bessemer
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Slate Medicines Secures $130M Series A Funding Led by RA Capital, Forbion and Foresite Capital
Corxel Secures $287M Series D1 Funding to Advance Oral GLP-1 Obesity Pill
Avalanche Energy Raises $29M in New Funding Led by RA Capital Management
VitriVax Raises $17.25M Series B Led by Adjuvant Capital and RA Capital
Hemab Therapeutics Raises $157M in Series C Led by Sofinnova Partners
